Carruthers R Michael
Known title: Chief Financial OfficerCIK: 0001644467
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,428 | $19K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,314 | $22K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,209 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 70,000 | $50K | 10/11/2024 | View on chart |
| OKUR | ▲ Buy | Grant | 874 | — | 10/4/2024 | View on chart |
| OKUR | ▲ Buy | Grant | 4,065 | — | 10/4/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 46,068 | $89K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 46,068 | $1.3M | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,064 | $116K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 24,960 | $714K | 9/20/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 50,000 | $97K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 50,000 | $1.4M | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,157 | $41K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 90,000 | $174K | 1/23/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 90,000 | $1.4M | 1/23/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,000 | $7K | 6/22/2023 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,336 | $12K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 9,000 | $6K | 5/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.